miR-155 inhibition decreases WM and CLL proliferation in the context of the BM milieu. (A) qRT-PCR analysis of miR-155 levels in WM stroma (n = 10) compared with normal stroma (n = 3). Data are shown as means ± SD. **P < .01. (B) BCWM1 or MEC1 cells were treated with 20μM anti–miR-155 or scramble control for 48 hours, followed by coculture with stromal cells from WM patients. Cell proliferation was evaluated by [H]³ thymidine uptake assay. Experiments were performed in triplicate and repeated 3 times. Data are shown as means ± SD. *P < .05; **P < .01. (C) BCWM1 or MEC1 cells were cocultured with stromal cells from wild-type or miR-155^−/− mice, and cell proliferation was measured by [H]³ thymidine uptake assay. Experiments were performed in triplicate and repeated 3 times. Data are shown as means ± SD. **P < .01. (D) BCWM1 or MEC1 cells were treated with 20μM anti–miR-155 or scramble control for 48 hours, followed by cocultured with stromal cells from wild-type or miR-155^−/− mice. Cell proliferation was measured by [H]³ thymidine uptake assay. Experiments were performed in triplicate and repeated 3 times. Data are shown as means ± SD. *P < .05; **P < .01.